Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Rather, the observed increased risk of developing breast cancer might be the result of a coordinated effect of multiple SNPs forming a risk haplotype in the second intron of FGFR2.
|
24265722 |
2013 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These data provide evidence that genetic variation in FGFR2 influences radiation-induced breast cancer risk.
|
22144180 |
2012 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Moreover, signaling through FGFR2, a known risk factor in breast cancer development, augmented these interactions and further repressed ESR1 target gene expression.
|
29180470 |
2018 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Other genes conferring an increased risk for breast cancer include ATM, CHEK2, PALB2, BRIP1 and genome-wide association studies have identified lower penetrance alleles including FGFR2, a minor allele of which is associated with breast cancer.
|
18575892 |
2008 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
One-third of these loci affected breast cancer oncogenes, whose amplifications were validated with specific probes: 17q12 (two cell lines with ERBB2 amplifications), 11q13 (two with cyclin-D1), 8p11-p12 (two with FGFR1) and 10q25 (one with FGFR2).
|
10604729 |
1999 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The FGFR2 locus is known to be associated with breast cancer risk.
|
27764800 |
2016 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Recent studies have linked FGFR1 expression and single nucleotide polymorphisms in FGFR2 to breast cancer.
|
19601767 |
2009 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
There was no significant association between the risk of breast cancer and FGFR2 (C906T).
|
19469636 |
2009 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genetic variation in FGFR2, identified by rs1219648, may account for a substantial fraction of breast cancer in Arab (12%), Ashkenazi (15%), and Sephardi Jewish (22%) populations.
|
18483326 |
2008 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Only 5 out of 9 GWAS breast cancer loci were found to be significantly associated with breast cancer in Tunisians: The rs1219648 (G vs. A allele: OR = 1.36, P = 1 × 10(-3)) and rs2981582 (A vs. G allele: OR = 1.55, P = 3 × 10(-6)) of FGFR2 gene; the rs8051542 of the TNRC9 gene (T vs. C allele: OR = 1.40, P = 4 × 10(-4)); the rs889312 of the MAP3K1 gene (C vs. A allele: OR = 1.33, P = 3 × 10(-3)) and the rs13281615 located on 8q24 (G vs. A allele: OR = 1.21, P = 0.03).
|
22910930 |
2012 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In tumor cell lines displaying molecular alterations in potential nintedanib targets, the inhibitor demonstrates direct antiproliferative effects: in the NSCLC cell line NCI-H1703 carrying a PDGFR<i>α</i> amplification (ampl.); the gastric cancer cell line KatoIII and the breast cancer cell line MFM223, both driven by a FGFR2 amplification; AN3CA (endometrial carcinoma) bearing a mutated FGFR2; the acute myeloid leukemia cell lines MOLM-13 and MV-4-11-B with FLT3 mutations; and the NSCLC adenocarcinoma LC-2/ad harboring a CCDC6-RET fusion.
|
29263244 |
2018 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We interrogated eight SNPs in intron 2 of the FGFR2 gene for 1,676 women who developed breast cancer during trial follow-up (1993-2005).
|
20056625 |
2010 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
When qPCR-identified amplifications in FGFR1, FGFR2, or FGF3 were grouped to define an FGF pathway-amplified breast cancer in HR-positive patients, the mean reduction in target lesions was 21.1% compared with a 12.0% increase in patients who did not present with FGF pathway-amplified breast cancer.
|
23658459 |
2013 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We confirmed associations between rs13387042 (2q35), rs4973768 (SLC4A7), rs10941679 (5p12), rs2981582 (FGFR2), rs3817198 (LSP1), rs3803662 (TOX3), and rs6504950 (STXBP4) with breast cancer.
|
23893088 |
2013 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The FGFR2 gene was associated with risk of overall breast cancer (P = 0.002) and ER-positive breast cancer (P = 0.002).
|
26743380 |
2016 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We replicated previously reported breast cancer susceptibility alleles in these BRCA2 mutation carriers and for several regions (including FGFR2, MAP3K1, CDKN2A/B, and PTHLH) identified SNPs that have stronger evidence of association than those previously published.
|
23544012 |
2013 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
These results confirm that FGFR2 and MAP3K1 are involved in breast cancer susceptibility and confer their effects primarily in ER+ and PR+ tumors.
|
19028704 |
2009 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Fibroblast growth factor 1 (FGF1) and RNA binding protein fox-1 homolog 2 (RBFOX2), which are functionally related to FGFR2, may also associate with breast cancer risk.
|
23143756 |
2013 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The distribution of genotypes of 2q35 were significantly different between the breast cancer group and the control group (p=0.035), while the distributions for 3p24, 17q23, and FGFR2 did not produce statistically significant differences (p>0.05).
|
22287734 |
2012 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We have revealed significant association of FGFR2 and MAP3K1 polymorphisms with breast cancer.
|
29372690 |
2017 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Significant association with BC was confirmed in 2 SNPs: rs2981582 FGFR2 and rs889312 MAP3K1, and the odds ratios of homozygotes with two risk alleles in both SNP's were higher than in heterozygotes with one mutant allele, as follows: FGFR2 TT: 1.953 (95%CI 1.014-3.834, p = 0.049), CT 1.771 (95%CI 1.088-2.899, p = 0.026) and MAP3K1 CC 2.894 (95%CI 1.028-9.566, p = 0.048), AC 1.760 (95%CI 1.108-2.813, p = 0.019).
|
31002855 |
2019 |
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
These data provide the first evidence for FGFR2 down-regulation in breast carcinomas harboring intron 2 SNPs.
|
20348248 |
2010 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Of the 9 polymorphisms investigated, 7 were associated with breast cancer for BRCA2 carriers (FGFR2, TOX3, MAP3K1, LSP1, 2q35, SLC4A7, 5p12, P = 7 × 10(-11) - 0.03), but only TOX3 and 2q35 were associated with the risk for BRCA1 carriers (P = 0.0049, 0.03, respectively).
|
21118973 |
2010 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
FGFR2 rs2981575 had the strongest association with breast cancer risk (per allele HR = 1.28, 95% CI 1.18-1.39, ).
|
21060860 |
2010 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A three-stage genome-wide association study recently identified single nucleotide polymorphisms (SNPs) in five loci (fibroblast growth receptor 2 (FGFR2), trinucleotide repeat containing 9 (TNRC9), mitogen-activated protein kinase 3 K1 (MAP3K1), 8q24, and lymphocyte-specific protein 1 (LSP1)) associated with breast cancer risk.
|
18437204 |
2008 |